UCB 35440

Drug Profile

UCB 35440

Alternative Names: UCB 35440-3

Latest Information Update: 04 Feb 2017

Price : $50

At a glance

  • Originator UCB
  • Class Antiallergics; Antiasthmatics; Piperazines
  • Mechanism of Action 5-lipoxygenase inhibitors; Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma

Most Recent Events

  • 03 Feb 2017 Discontinued - Phase-I for Allergic rhinitis (PO)
  • 03 Feb 2017 Discontinued - Phase-II for Asthma (PO)
  • 05 Aug 2004 Suspended - Phase-I for Allergic rhinitis (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top